Peptide News Digest

#Glp-1-Gip-Glucagon

2 stories

Clinical Trials · View digest

Eli Lilly (NYSE: LLY) Is Expected to Submit Retatrutide (Once-Weekly Injectable Triple GLP-1/GIP/Glucagon Receptor Agonist Peptide) to the FDA in Late 2026 or 2027 Following the Seven Phase 3 TRIUMPH-Program Readouts Expected Across 2026 (Including TRIUMPH-1 in Obesity Meeting Primary Endpoint With 28.7% Mean Weight Loss at 68 Weeks at the 12 mg Dose, TRIUMPH-4 in Obesity Plus Knee Osteoarthritis Documenting 28.7% Weight Loss and 75.8% Reduction in WOMAC Pain Scores With More Than 1 in 8 Retatrutide-Treated Patients Completely Free From Knee Pain, and Additional Readouts in Type 2 Diabetes, Obstructive Sleep Apnea, and Cardio-Renal-Metabolic Indications); Potential FDA Approval Expected in 2027-2028 Would Position Retatrutide as the Highest-Magnitude Weight Loss Obesity Drug

Eli Lilly (NYSE: LLY) is expected to submit retatrutide (once-weekly injectable triple GLP-1/GIP/glucagon receptor agonist peptide) to the FDA in late 2026 or 2027 following the seven Phase 3 TRIUMPH-program readouts expected across 2026. Program status: TRIUMPH-1 in obesity met primary endpoint with 28.7% mean weight loss at 68 weeks at the 12 mg dose; TRIUMPH-4 in obesity plus knee osteoarthritis documented 28.7% weight loss and 75.8% reduction in WOMAC pain scores with more than 1 in 8 retatrutide-treated patients completely free from knee pain at study end. Additional Phase 3 readouts expected across 2026 in type 2 diabetes, obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic indications. If the full TRIUMPH package supports approval, retatrutide would be the highest-magnitude weight loss obesity drug on record (extending the ceiling from tirzepatide's 25.5% at 84 weeks in REDEFINE 4 head-to-head to 28.7% in TRIUMPH-4). The triple-receptor mechanism activates GLP-1 (appetite suppression via hypothalamic pathways), GIP (adipose tissue effects plus central appetite contribution), and glucagon (hepatic effects plus thermogenesis), producing broader tissue coverage than dual-agonist tirzepatide or amylin-plus-GLP-1 CagriSema. Approval is anticipated in 2027-2028 and would reshape the competitive dynamics for the entire obesity drug class, with substantial implications for Novo Nordisk's franchise defense strategy following the August 2026 broker downgrade and Wegovy 7.2 mg higher-dose FDA review submission.

Clinical Trials · View digest

Kailera Therapeutics (NASDAQ: KLRA) Reported August 12 Q2 2026 Financial Results and Disclosed an Active Investigational New Drug (IND) Application With the US FDA for Ribupatide Oral (KAI-9531-T), a Triple Agonist (GLP-1/GIP/Glucagon) Peptide for Obesity Being Co-Developed With Hengrui Pharma, With Global Phase 3 Obesity Trials Planned to Initiate in H1 2027 Following Hengrui's Phase 2 Trial in Adults With Obesity That Documented Up to 12.1% Mean Weight Loss With No Observed Plateau at Week 26 and Up to 38.6% of Participants Achieving at Least 15% Weight Loss at the 25 mg and 50 mg Once-Daily Oral Doses; A Ribupatide Injection Phase 2b High-Dose Trial in Obesity Is Fully Enrolled With Data Anticipated in Mid-2027

Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a triple agonist (GLP-1, GIP, and glucagon receptor) peptide for obesity being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide competes mechanistically with Eli Lilly's retatrutide (once-weekly injectable triple agonist, roughly 28.7% weight loss at 68 weeks in Phase 3 TRIUMPH-4) in the triple-agonist class. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.